- Home
- AAM vs FHTX Comparison
AAM vs FHTX Comparison
Compare AAM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAM
- FHTX
- Stock Information
- Founded
- AAM 2024
- FHTX 2015
- Country
- AAM United States
- FHTX United States
- Employees
- AAM N/A
- FHTX N/A
- Industry
- AAM
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- AAM
- FHTX Health Care
- Exchange
- AAM Nasdaq
- FHTX Nasdaq
- Market Cap
- AAM 440.6M
- FHTX 513.7M
- IPO Year
- AAM 2024
- FHTX 2020
- Fundamental
- Price
- AAM $10.06
- FHTX $9.11
- Analyst Decision
- AAM
- FHTX Strong Buy
- Analyst Count
- AAM 0
- FHTX 5
- Target Price
- AAM N/A
- FHTX $16.00
- AVG Volume (30 Days)
- AAM 302.6K
- FHTX 123.1K
- Earning Date
- AAM 01-01-0001
- FHTX 11-04-2024
- Dividend Yield
- AAM N/A
- FHTX N/A
- EPS Growth
- AAM N/A
- FHTX N/A
- EPS
- AAM N/A
- FHTX N/A
- Revenue
- AAM N/A
- FHTX $25,515,000.00
- Revenue This Year
- AAM N/A
- FHTX N/A
- Revenue Next Year
- AAM N/A
- FHTX $15.40
- P/E Ratio
- AAM N/A
- FHTX N/A
- Revenue Growth
- AAM N/A
- FHTX N/A
- 52 Week Low
- AAM $9,600.00
- FHTX $2.70
- 52 Week High
- AAM $15,000.00
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- AAM N/A
- FHTX 61.38
- Support Level
- AAM N/A
- FHTX $7.95
- Resistance Level
- AAM N/A
- FHTX $9.54
- Average True Range (ATR)
- AAM 0.00
- FHTX 0.56
- MACD
- AAM 0.00
- FHTX 0.19
- Stochastic Oscillator
- AAM 0.00
- FHTX 82.08
About AAM AA Mission Acquisition Corp. Class A Ordinary Shares
AA Mission Acquisition Corp is a blank check company.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.